News | April 12, 2022
Wacker, CordenPharma to produce mRNA vaccines for Germany
Both companies have been selected for stand-by production by German government
Both companies have been selected for stand-by production by German government
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
Subscribe To Our Newsletter & Stay Updated
